Zacks Research Issues Positive Forecast for CL Earnings

Colgate-Palmolive Company (NYSE:CL) – Equities researchers at Zacks Research boosted their Q3 2026 earnings per share estimates for Colgate-Palmolive in a report released on Friday, August 14th. Zacks Research analyst Team now anticipates that the company will earn $0.92 per share for the quarter, up from their prior forecast of $0.91. The consensus estimate for Colgate-Palmolive’s current full-year earnings is $3.86 per share. Zacks Research also issued estimates for Colgate-Palmolive’s Q4 2026 earnings at $0.97 EPS, FY2026 earnings at $3.85 EPS, Q1 2027 earnings at $1.00 EPS, Q2 2027 earnings at $1.03 EPS, FY2027 earnings at $4.05 EPS and FY2028 earnings at $4.36 EPS.

Several other research firms have also recently weighed in on CL. Citigroup boosted their price objective on Colgate-Palmolive from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Royal Bank Of Canada increased their price objective on Colgate-Palmolive from $102.00 to $104.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. JPMorgan Chase & Co. lowered their price objective on shares of Colgate-Palmolive from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Barclays boosted their target price on shares of Colgate-Palmolive from $80.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Piper Sandler increased their price target on shares of Colgate-Palmolive from $92.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Twelve analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Colgate-Palmolive Trading Down 1.9%

Shares of NYSE:CL opened at $90.22 on Monday. The company has a debt-to-equity ratio of 13.82, a quick ratio of 0.67 and a current ratio of 1.03. The stock’s 50-day moving average is $91.76 and its 200-day moving average is $90.05. The company has a market cap of $71.92 billion, a P/E ratio of 35.80, a P/E/G ratio of 4.48 and a beta of 0.33. Colgate-Palmolive has a 52-week low of $74.54 and a 52-week high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, July 31st. The company reported $0.99 EPS for the quarter, topping the consensus estimate of $0.95 by $0.04. The firm had revenue of $5.36 billion for the quarter, compared to the consensus estimate of $5.36 billion. Colgate-Palmolive had a net margin of 9.68% and a return on equity of 464.63%. The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 EPS.

Institutional Trading of Colgate-Palmolive

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kemnay Advisory Services Inc. acquired a new position in Colgate-Palmolive during the 4th quarter worth about $25,000. CBIZ Investment Advisory Services LLC increased its position in Colgate-Palmolive by 86.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 323 shares of the company’s stock valued at $26,000 after acquiring an additional 150 shares in the last quarter. TD Capital Management LLC increased its position in Colgate-Palmolive by 61.4% in the 4th quarter. TD Capital Management LLC now owns 326 shares of the company’s stock valued at $26,000 after acquiring an additional 124 shares in the last quarter. Triumph Capital Management raised its stake in shares of Colgate-Palmolive by 62.9% in the fourth quarter. Triumph Capital Management now owns 329 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the last quarter. Finally, Jessup Wealth Management Inc bought a new position in shares of Colgate-Palmolive in the fourth quarter worth about $26,000. 80.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, CEO Noel R. Wallace sold 161,021 shares of Colgate-Palmolive stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $91.92, for a total value of $14,801,050.32. Following the completion of the transaction, the chief executive officer owned 362,231 shares in the company, valued at approximately $33,296,273.52. The trade was a 30.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John T. Cahill sold 4,170 shares of Colgate-Palmolive stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total value of $389,352.90. Following the completion of the transaction, the director owned 28,373 shares of the company’s stock, valued at approximately $2,649,187.01. The trade was a 12.81% decrease in their position. The SEC filing for this sale provides additional information. 0.43% of the stock is owned by insiders.

Colgate-Palmolive Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Monday, July 20th were paid a $0.53 dividend. The ex-dividend date was Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.3%. Colgate-Palmolive’s payout ratio is 84.13%.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.